English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, August 24, 2022
中国抗体宣布SN1011针对视神经脊髓炎谱系疾病的新药研究申请获国家药监局批准
中國抗體宣佈SN1011針對視神經脊髓炎譜系疾病的新藥研究申請獲國家藥監局批准
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
Friday, July 8, 2022
SinoMab Received the Highest Subsidy from HKSTP
中国抗体获香港科学园最高专项补贴
中國抗體獲香港科學園最高專項補貼
Tuesday, June 21, 2022
中国抗体的旗舰产品舒西利单抗SM03的作用机理在美国免疫领域权威期刊the Journal of Immunology上成功发表
中國抗體的旗艦產品舒西利單抗SM03的作用機理在美國免疫領域權威期刊the Journal of Immunology上成功發表
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.
Wednesday, June 15, 2022
中国抗体在美国完成SM17 I期临床试验首例健康受试者给药

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575